| AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
Onpattro vs Vyndamax
Side-by-side clinical, coverage, and cost comparison for amyloidosis, hereditary, transthyretin-related.Deep comparison between: Onpattro vs Vyndaqel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyndaqel has a higher rate of injection site reactions vs Onpattro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyndaqel but not Onpattro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Onpattro
Vyndaqel
At A Glance
IV infusion
Every 3 weeks
TTR-directed siRNA
Oral
Daily
TTR stabilizer
Indications
- AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
- AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
Dosing
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED 0.3 mg/kg IV infusion once every 3 weeks for patients weighing less than 100 kg; 30 mg IV infusion once every 3 weeks for patients weighing 100 kg or more; infuse over approximately 80 minutes.
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily; VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Upper respiratory tract infections, infusion-related reactions, dyspepsia, dyspnea, muscle spasms, arthralgia, erythema, bronchitis, vertigo
Serious Atrioventricular heart block (including complete AV block), extravasation
Postmarketing Syncope, pruritus (as symptoms of infusion-related reactions)
—
Pharmacology
Patisiran is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference, resulting in a reduction of serum TTR protein and TTR protein deposits in tissues.
Tafamidis is a selective stabilizer of TTR (transthyretin) that binds to thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Onpattro
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Vyndaqel
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Onpattro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyndaqel
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Onpattro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Vyndaqel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Amyloidosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Amyloidosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OnpattroView full Onpattro profile
VyndaqelView full Vyndaqel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.